Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Change in Receivables (2016 - 2025)

OptimizeRx's Change in Receivables history spans 16 years, with the latest figure at -$1.3 million for Q3 2025.

  • For Q3 2025, Change in Receivables fell 171.19% year-over-year to -$1.3 million; the TTM value through Sep 2025 reached $6.0 million, up 2550.0%, while the annual FY2024 figure was $2.2 million, 75.12% down from the prior year.
  • Change in Receivables for Q3 2025 was -$1.3 million at OptimizeRx, down from $792000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $12.0 million in Q4 2024 and bottomed at -$6.4 million in Q1 2024.
  • The 5-year median for Change in Receivables is $227000.0 (2023), against an average of $505742.5.
  • The largest annual shift saw Change in Receivables surged 415.99% in 2023 before it crashed 2402.64% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $4.1 million in 2021, then grew by 12.26% to $4.6 million in 2022, then surged by 108.88% to $9.6 million in 2023, then grew by 25.25% to $12.0 million in 2024, then tumbled by 110.74% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Change in Receivables are -$1.3 million (Q3 2025), $792000.0 (Q2 2025), and -$5.5 million (Q1 2025).